BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 20 Best Investments in 2026.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is next on our list.

TheFly reported on February 18 that Wells Fargo & Company increased its price target for BMRN from $70 to $75 while keeping an Overweight rating. The firm believes the upcoming Transcon-CNP PDUFA may mark the final negative catalyst for BMRN, and its sum-of-the-parts analysis indicates the stock is trading below its value excluding Voxzogo. According to Wells Fargo, the current share price presents a compelling opportunity for purchase.

Furthermore, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported on February 12 that it had completed the $850 million offering of 5.500% senior unsecured notes that mature in 2034 and were issued at par. In addition to other term loan arrangements and available funds, the proceeds are primarily intended to support the upcoming acquisition of Amicus Therapeutics and related transaction expenses.

The notes' proceeds were placed in escrow pending the deal's completion, with the stipulation that they be redeemed at full principal plus accrued interest in the event that the acquisition is not completed by the deadline. In addition to having normal covenant restrictions and being guaranteed by certain subsidiaries, the notes were made available to eligible institutional buyers and non-U.S. investors through a private offering.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biopharmaceutical company developing and commercializing therapies for rare genetic diseases, focusing on enzyme replacement and gene-targeted treatments.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

.

and 

.

Disclosure: None.